

## NSCLC Indication Screen

### Clinically Relevant Lung Cancer PDX Cohort Screening Opportunity

Participate in the Champions Oncology Indication Screen for lower cost, large scale PDX pharmacology studies across 35 Clinically Relevant NSCLC PDX Models

Enrollment Open Now through November 30th

Models available on a first-come first-served basis

The details on the Champions' NSCLC Indication Screen are detailed below:

### The Champions' NSCLC Indication Screen






NGS Data (WES and RNASeq) is freely available for all models. Free FFPE/Snap frozen samples available at no cost for target validation.

- Significant cost savings compared to stand-alone studies
- Models include:
  - KRas, BRAF, HER family Mutations
  - ALK, ROS1, RET Fusions
  - HER2, MET multi-copy Amplifications
- No minimum enrollment
- Patient treatment history and PDX drug response data available
- Free terminal tumor collections
- Flow cytometry, IHC and Nanostring gene expression analysis available
- Enrollment period ends November 30th


### Limited Availability

Please contact us today at [championsoncology.com/contact-us](http://championsoncology.com/contact-us) to learn more about models still available and take advantage of this opportunity before it ends on November 30th

## Clinical graphs



### Platinum therapy PDX model screens



### Taxane therapy PDX model screens

